These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11502466)

  • 1. Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
    Peehl DM; Seto E; Feldman D
    Urology; 2001 Aug; 58(2 Suppl 1):123-6. PubMed ID: 11502466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
    Peehl DM; Seto E; Hsu JY; Feldman D
    J Urol; 2002 Oct; 168(4 Pt 1):1583-8. PubMed ID: 12352462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
    Dixon SC; Zalles A; Giordano C; Lush RM; Venzon D; Reed E; Figg WD
    Cancer Lett; 1997 Feb; 113(1-2):111-6. PubMed ID: 9065809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells.
    Segersten U; Björklund P; Hellman P; Akerström G; Westin G
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):399-404. PubMed ID: 17302875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Cancer; 1993 Feb; 71(3 Suppl):1068-73. PubMed ID: 8428329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
    Yee SW; Campbell MJ; Simons C
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
    Peehl DM; Feldman D
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
    Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
    Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
    J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP24A1 inhibition enhances the antitumor activity of calcitriol.
    Muindi JR; Yu WD; Ma Y; Engler KL; Kong RX; Trump DL; Johnson CS
    Endocrinology; 2010 Sep; 151(9):4301-12. PubMed ID: 20591973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
    Keisner SV; Shah SR; Jean GW; Ussery SM; Dowell JE
    Ann Pharmacother; 2010 Oct; 44(10):1538-44. PubMed ID: 20841515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
    Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
    Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D-related therapies in prostate cancer.
    Johnson CS; Hershberger PA; Trump DL
    Cancer Metastasis Rev; 2002; 21(2):147-58. PubMed ID: 12465754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D in prostate cancer.
    Trump DL; Aragon-Ching JB
    Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel concepts in androgen receptor blockade.
    Hsieh AC; Ryan CJ
    Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.